Breaking News, Collaborations & Alliances

BARDA Funds Development of Tangen Biosciences’ Multi-Target Platform

Also awards Tangen a new contract for Point-of-Care COVID-19 molecular test

By: Contract Pharma

Contract Pharma Staff

The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) has awarded Tangen the Second Option of a contract to develop a molecular diagnostic platform that can be used by Tangen Biosciences Inc. to rapidly develop infectious disease tests. Last week, BARDA also announced that Tangen was awarded a separate contract to develop a rapid SARS-CoV-2 test for detection of COVID-19 infection utilizing Tangen’s platform.   The molecular diagnostic p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters